Navigation Links
Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research

SOUTH SAN FRANCISCO, Calif., April 13, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in Los Angeles, California.

Data being presented in a poster session will focus on non-clinical data on SNS-032, a highly selective and potent inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9 that is currently in a Phase 1 clinical trial for B-cell malignancies. Abstract #1815: "SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226" will be presented on Monday, April 16, 2007 from 8:00 a.m. to 12:00 p.m. in poster section 7, board #1.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute myeloid leukemia for its lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitor compound, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314 is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of targeted cancer therapeutics. Sunes
'"/>




Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:12/4/2009)... OMAHA, Neb., Dec. 4 Amber Pharmacy announced today ... Health Care, Inc. (ACHC) for specialized pharmacy services. For ... care programs and services to meet the unique needs ... leading providers of services to transplant programs. They work ...
(Date:12/4/2009)... Shared Imaging, LLC, an independent provider of CT, ... hospitals and healthcare providers, is excited to announce ... Ambulatory Health Care, a nationally-recognized, prestigious gold seal ... care. Shared Imaging accreditation is system-wide for its ...
(Date:12/4/2009)... stored in tin cans and car trunks ,, ... urged the Senate to defeat the Dorgan Importation plan encompassed ... importation amendment is poised to open our borders, allowing our ... to be endangered. We could soon be getting drugs ...
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Preimplantation genetic diagnosis may pose neurological risks 9300 1Preimplantation genetic diagnosis may pose neurological risks 9300 2A Drug Dispensing Contact Lens 52295 1A Drug Dispensing Contact Lens 52295 2A Drug Dispensing Contact Lens 52295 3Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 1Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 2Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 3Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 4
... 11 June 2007 - Clavis Pharma (OSE: CLAVIS),presented ... Phase I/II,study with ELACYT in hematologic cancers during ... European Hematology Association (EHA) in,Vienna. ELACYT is a ... hematologic cancers as well as for solid tumours. ...
... researchers at the,National Cancer Institute (NCI), part of the ... genes that are turned on, or,expressed, at high levels ... and humans. These genes, and the proteins they,encode, are ... cut off a tumor's blood supply without affecting,the blood ...
Other Medicine Technology:Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA 2NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 2NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 3
(Date:12/6/2009)... Medical College of Wisconsin, in Milwaukee, found a substantial ... cell disease complications in children. Barriers to its use ... also identified. The study led by Amanda M. ... Medical College and Children,s Research Institute at the Children,s ... Society of Hematology meeting Dec. 7, 2009, in New ...
(Date:12/6/2009)... Internet Sleep Disorders information and Treatment site ... sleep problems with herbal or natural sleep aids ... ,insomnia remedies for a good cause. The submissions ... Natural Sleep Aids ,Encyclopedia, by YOU, to be ... The site will donate 100% of the proceeds ...
(Date:12/5/2009)... What: Cuts for a Cause ,, ... cancer and other terminal illnesses affecting children. All proceeds from ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors ... restaurant in Falls Church for all guests. Hoa Lai, a ...
(Date:12/5/2009)... ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 ... their 40th birthday without ever tying the knot, since research ... married folks. And, um, isn,t there something wrong with those ... A new study looking at psychological measures shows that never-married ...
(Date:12/4/2009)... ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: ... has set the regular 2010 Annual Meeting of Stockholders for ... 2009. The meeting will be held at the Crowne Plaza ... 4:30 p.m. PT. ,, The meeting will be webcast by ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2
... 20 Ambulatory Services of,America, Inc. announced the ... venture to provide outpatient radiation oncology services. ROSA ... Center, LP and ASA,s,subsidiary, Radiation Oncology Services of ... a radiation therapy facility in Denton, Texas that ...
... Into a User,s New ... Google Health Profile, ANN ... a variety of integrated healthcare services,announced today that it is integrated ... launched yesterday which allows users to,store, organize, and manage their medical ...
... 20 With the financial support of,Sechrist Industries, ... the Ohio State University Medical Center has begun ... stroke models. CMIS is a,multidisciplinary center dedicated to ... studies pertaining to the techniques and,technology of minimally ...
... A major study published today in Nature Nanotechnology suggests ... for the nanotechnology revolution could be as harmful as ... established methods to see if specific types of nanotubes have ... lung lining that can take 30-40 years to appear following ...
... trust magazines or advertising for,treatment information, NEW ... Safety ( http://www.injectablesafety.org ) and the health and,beauty ... a joint survey reporting that 40% of consumers ... 58% of consumers feel FDA approval,of an injectable ...
... CHELMSFORD, Mass., May 20 Mercury Computer,Systems, Inc. ... specialized,high-performance computing solutions for complex image, sensor, and ... overview,of the Company,s business on Thursday, May 29, ... The Conference will be,held at the New York ...
Other Medicine News:Health News:Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP 2Health News:UNIVAL, Inc. Becomes a Google Health(TM) Integrated Service 2Health News:Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims 2Health News:Carbon nanotubes that look like asbestos, behave like asbestos 2Health News:Carbon nanotubes that look like asbestos, behave like asbestos 3Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 2Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 3Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 4Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
... an average 5:1 increase in usage time at ... a standard cannula. , ,The combination of ... oxygen patients a superior alternative to liquid oxygen. ... , ,NOTE: Each ...
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
Medicine Products: